Bank of America Corp DE Purchases 176,703 Shares of Maze Therapeutics, Inc. $MAZE

Key Points

• Bank of America significantly increased its Maze Therapeutics stake by purchasing 176,703 shares, bringing its holdings to 195,084 shares valued at approximately $5.8 million, or 0.35% of the company.
• Analyst sentiment remains broadly positive: Maze has an average “Buy” rating and a consensus price target of $66, although some firms maintain “Sell” ratings.
• Insiders sold 108,110 shares worth about $3.1 million over the past quarter. Maze recently reported a quarterly loss of $0.76 per share, while its stock opened at $29.58 and has traded between $13.67 and $53.65 over the past year.

Bank of America Corp DE increased its holdings in Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) by 961.3% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 195,084 shares of the company's stock after buying an additional 176,703 shares during the period. Bank of America Corp DE owned 0.35% of Maze Therapeutics worth $5,823,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Royal Bank of Canada increased its stake in Maze Therapeutics by 128.3% in the 4th quarter. Royal Bank of Canada now owns 646 shares of the company's stock worth $27,000 after acquiring an additional 363 shares during the last quarter. Ameritas Investment Partners Inc. lifted its position in Maze Therapeutics by 82.6% during the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company's stock valued at $42,000 after purchasing an additional 738 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in Maze Therapeutics in the 4th quarter worth approximately $43,000. Russell Investments Group Ltd. grew its stake in Maze Therapeutics by 947.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company's stock worth $49,000 after buying an additional 1,725 shares in the last quarter. Finally, Legal & General Group Plc increased its holdings in shares of Maze Therapeutics by 387.0% in the 2nd quarter. Legal & General Group Plc now owns 4,242 shares of the company's stock worth $52,000 after buying an additional 3,371 shares during the last quarter.

Analyst Ratings Changes

A number of research firms have weighed in on MAZE. TD Cowen upgraded Maze Therapeutics to a "strong-buy" rating in a research report on Monday. BTIG Research reiterated a "buy" rating and set a $46.00 price objective on shares of Maze Therapeutics in a research report on Wednesday, August 12th. Wall Street Zen cut Maze Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, August 15th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Maze Therapeutics in a research report on Wednesday, June 24th. Three analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Maze Therapeutics currently has an average rating of "Buy" and an average target price of $66.00.

Insider Buying and Selling

In other Maze Therapeutics news, CMO Harold Bernstein sold 16,142 shares of the firm's stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $27.61, for a total transaction of $445,680.62. Following the completion of the transaction, the chief marketing officer owned 16,142 shares of the company's stock, valued at approximately $445,680.62. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Atul Dandekar sold 7,500 shares of the business's stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $27.34, for a total value of $205,050.00. Following the completion of the sale, the insider directly owned 26,250 shares in the company, valued at $717,675. This trade represents a 22.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 108,110 shares of company stock valued at $3,057,531 over the last quarter. Corporate insiders own 5.30% of the company's stock.

Maze Therapeutics Stock Performance

Shares of NASDAQ:MAZE opened at $29.58 on Thursday. Maze Therapeutics, Inc. has a 12 month low of $13.67 and a 12 month high of $53.65. The company has a current ratio of 18.31, a quick ratio of 18.31 and a debt-to-equity ratio of 0.09. The company has a 50-day moving average price of $28.64 and a 200-day moving average price of $32.04. The company has a market cap of $1.64 billion, a price-to-earnings ratio of -11.74 and a beta of 2.21.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last posted its earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.76). As a group, equities analysts anticipate that Maze Therapeutics, Inc. will post -2.72 EPS for the current year.

About Maze Therapeutics

Maze Therapeutics, Inc NASDAQ: MAZE is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze's approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.